# Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

> **NCT01262482** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 41 (actual)

## Conditions studied

- Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01262482
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-10
- **Final completion:** 2011-12
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2012-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262482, "Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01262482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*